News Northwest Biotherapeutics, Inc. Börse Stuttgart

Stocks

NBYB

US66737P6007

Biotechnology & Medical Research

Market Closed - Börse Stuttgart Other stock markets 15:56:12 2026-07-14 EDT			5-day change	1st Jan Change
0.1500 ^EUR	-6.25%		-11.76%	-27.18%

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

All News

Mentions Relevance

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
04-21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-20	Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility	PR
11-14	Northwest Biotherapeutics: Q3 Earnings Snapshot	AQ
11-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
25-10-31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
25-10-26	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
25-10-24	Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed	PR
25-10-23	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
25-08-27	Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.	PR
25-08-26	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
25-08-18	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
25-08-18	Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	PR
25-08-14	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
25-08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-29	Northwest Biotherapeutics, Inc. announced that it expects to receive $2.85 million in funding from Yorkville Advisors Global LP	CI